OPEN END TURBO LONG - ZEALAND PHARMA | Real-time Bid/Ask 05:27:27 03/06/2024 pm IST | ||
| 1.68 EUR / 1.73 EUR | -6.32% |
|
| 1 month | +7.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 1.79 | -1.65% |
| 31/24/31 | 1.82 | +30.00% |
| 30/24/30 | 1.4 | -6.04% |
| 29/24/29 | 1.49 | -3.25% |
| 28/24/28 | 1.54 | +6.94% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 12:35 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MG051M |
| ISIN | DE000MG051M7 |
| Date issued | 13/03/2024 |
| Strike | 510.1 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.27 € |
|---|---|
| Lowest since issue | 1.02 € |
| Spread | 0.05 € |
| Spread % | 2.91% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
639.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+22.84%
- Stock Market
- Certificates
- Certificat
